MiR-92b inhibitor promoted glioma cell apoptosis via targeting DKK3 and blocking the Wnt/beta-catenin signaling pathway
© Li et al.; licensee BioMed Central Ltd. 2013
Received: 3 August 2013
Accepted: 6 December 2013
Published: 11 December 2013
MiR-92b was upregulated in gliomas. However, the association of miR-92b with glioma cell apoptosis and survival remains unknown.
Proliferation capability of glioma cells upon tranfection with miR-92b mimics or inhibitors was detected by mutiple analyses, including MTT assays, colony formation assay. Apoptosis abilities of glioma cells were detected by flow cytometric analysis. The target of miR-92b was determined by luciferase reporter and western blot. The association of miR-92b with outcome was examined in twenty glioma patients.
MiR-92b expression was significantly increased in high-grade gliomas compared with low-grade gliomas, and positively correlated with the degree of glioma infiltration. Over-expression of miR-92b increased cell proliferation, whereas knockdown of miR-92b decreased cell proliferation via modulating the levels of the target, Target prediction analysis and a dual luciferase reporting assay confirmed that the inhibitory protein-coding Dickkopf-3 gene (DKK3) was a direct target of miR-92b. Furthermore, miR-92b could regulate the expression of downstream genes of the Wnt/beta-catenin signaling pathway, such as Bcl2, c-myc and p-c-Jun, in glioma cells. Finally, the increased level of miR-92b expression in high-grade gliomas confers poorer overall survival.
The present data indicates that miR-92b directly regulate cell proliferation and apoptosis by targeting DKK3 and act as prognostic factors for glioma patients.
A glioma is the most common form of neural malignancy. High grade glioma, especially glioblastoma, is a leading cause of brain cancer fatality involving highly invasive and neoplastic growth. Despite therapeutic advances, many patients suffer from tumor recurrence due to chemo- and radio- therapy resistance[1–3]. Increasing evidence suggests that the progression of a glioma is relative to the rate of both cell proliferation and apoptosis. Therefore, understanding the main regulatory mechanism of gliomas is key to the development of effective therapeutic approaches against this malignancy.
MicroRNAs (miRNAs) are small, endogenous, non-coding RNA molecules, which usually result in gene silencing by binding to complementary sequences in the three prime untranslated regions (3-UTRs) of target messenger RNA transcripts (mRNAs)[4–9]. The deregulation of miRNAs has been observed in various types of human malignancies, including lymphoma, colorectal cancer, lung cancer, breast cancer, papillary thyroid carcinoma, hepatocellular carcinoma and glioblastoma[10–13]. Accounting for approximately 1% of all the expressed human genes, miRNAs are predicted to regulate the expression of up to 1/3 of human protein-coding genes[14–17]. A few studies suggest that the downregulation of miRNAs may play a critical role in cancer progression by affecting not only proliferation but also apoptosis[18–20]. Primary brain tumors expressed higher levels of miR-92b than both primary tumors in other tissues and their metastases to the brain. In neuroblastoma, mir-92b was reported to modulate the expression of the inhibitory protein-coding Dickkopf-3 gene (DKK3). However, the underlying mechanism of mir-92b in gliomas has not been identified so far.
In the current study, we demonstrate that high levels of miR-92b expression in gliomas confer highly aggressive invasion and poorer overall survival. Knockdown of miR-92b decreased glioma cell prolifirelation, reduced apoptosis and up-regulated the expression of the target, DKK3, whereas ectopic expression of miR-92b exhibited the opposite effects. Furthermore, miR-92b could regulate the expression of downstream genes of the Wnt/beta-catenin signaling pathway, such as Bcl2, c-myc and p-c-Jun. These findings indicate that DKK3 is a critical target of miR-92b and that the microRNA could be critical therapeutic targets and survival predictors in glioma.
Materials and methods
The human glioma tissue samples and their corresponding nontumorous tissues were collected at the time of surgical resection at the Department of Pediatric Neurosurgery, Xinhua Hospital, Shanghai Jiao Tong University. Twenty frozen glioma specimens with clinical data were collected from January 2008 to June 2013, including 9 grade I-II tumors, 8 grade III tumors and 3 grade IV tumors. The glioma samples were deep-frozen using liquid nitrogen, stored at −80°C and were quantified by Real-time PCR. This study was approved by the Institutional Review Board of Xinhua hospital. Patients were followed by clinical and laboratory monitoring on a regular basis starting at definitive diagnosis. Disease-specific survival time was defined as the time from definitive diagnosis to disease-specific death.
The antibodies aganist c-jun, phospho-c-jun, JNK, phospho-JNK, DKK3, beta-catenin, Bcl-2, β-actin, caspase-3, Bax, c-myc were purchased from Santa Cruz Biotechnology (California, USA). The dual luciferase reporter assay system, the PGL3-Promoter, the PGL3-Basic and PRL-TK vectors were purchased from Promega (Promega Corporation, Wisconsin, USA). The miRNA mimics and siRNA were purchased from Biomics Biotechnologies (Nantong, China). All other chemicals were from Sigma- Aldrich unless otherwise stated.
Cell cultures and transfection
The human glioma cell lines U251, U87, A172 and SHG44, and human astrocytes (HA) (Cell Bank of the Chinese Academy of Science, Shanghai, China), were maintained in RPMI 1640 medium (Gibco Industries, Inc. Carlsbad, CA) with 10% fetal bovine serum (Gibco Industries, Inc.) at 37°C in a humid atmosphere wih 5% CO2. Cell transfection was performed using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.
Total RNA was extracted from eight glioma tissues using the miRVana miRNA Isolation Kit (Ambion, Carlsbad, USA) according to the manufacturer’s instructions. The samples were subsequently submitted to Shanghai Biotechnology Corporation (Shanghai, China) for array hybridization on an Agilent Human miRNA array (v.12.0). Each microarray chip was hybridized with a single sample labeled with either Cy3 or Cy5. Background subtraction and normalization were performed. The raw data were deposited at Shanghai Biotechnology Corporation (Shanghai, China) and have not been reported publicly up till the present moment. We selected the miRNAs that exhibited a difference in expression levels of at least 2-fold (p<0.05) between the glioma tissue samples and their corresponding nontumorous tissues.
RNA extraction and quantification
Total RNA was extracted using Trizol (Invitrogen Corporation, California, USA) according to the manufacturer’s instructions. Reverse transcription was performed using One Step PrimeScript®miRNA cDNA Synthesis Kit (Takara Bio Inc, Dalian, China). Real-time PCR was performed using SYBR®Premix Ex TaqTM II (Takara Bio Inc, Dalian, China) with an iCycler®thermal cycler (Bio-Rad, Hercules, USA).U6 RNA was used as a miRNA internal control. The primers of miR-92b was as follows: 5′-TATTGCACTCGTCCCGGCCT-3′.
Colony formation assay
U251 and U87 cells were transfected with miR-92b mimics, a control oligonucleotide and a miR-92b inhibitor. After the transfection, the U251 and U87 cells were counted and seeded in 12-well plates (in triplicates) at a density of 50 and 60 cells per well, respectively. The culture medium was replaced every 3 days. The number of colonies was counted on the sixth day after seeding. The rate of colony formation was calculated with the following equation: colony formation rate (%) = (number of colonies number of seeded cells) × 100%.
The MTT assay was used to determine cell viability. All the cells were seeded into 96-well culture plates (2×103 cells/well) in regular growth medium. The cells transfected with miR-92b mimics. control and inhibitors were grown for 4 days. One plate was developed immediately after the medium change and other plates were developed every 24 hours for 4 days. Assays were initiated by adding 20 L of MTT substrate to each well and incubating the cells for an additional 3 hours. Finally, the medium was removed and 200 L DMSO was added to each well. The absorbance was measured at 492 nm using an Automated Microplate Reader (Multiskan Ex, Lab systems, FIN).
Analysis was used to determine the relative expression levels of miRNAs. Total RNA was isolated using TRIZOLTM reagent (Promega Corporation, Wisconsin, USA) according to the supplier’s instruction. Reverse transcription was done using One Step PrimeScript® miRNA cDNA Synthesis Kit (TaKaRa Biotechnology Ltd, Shandong, CHN). Real-time PCR was performed using SYBR Green Supermix with an iCycler®thermal cycler (Bio-Rad Laboratories Inc, California, USA).Primers of all genes were in Supple-mentary. The data were collected and analyzed using the comparative Ct (threshold cycle) method using GADPH as the reference gene.
MicroRNA target prediction
The target genes of miR-92b were predicted by the following computer-aided algorithms: TargetScan Human Release 6.2 (http://www.targetscan.org).
The 3′UTR of human DKK3, containing the putative target sites for miR-92b, was amplified by PCR. The wild-type and mutant inserts were transfected into the PGL3-promoter vector. Dual-Luciferase reporter assays were performed according to the manufacturer’s instructions (Promega, Madison, WI) as previously described.
Flow cytometric analysis of apoptosis
Cells (6 *104/well) were plated in 6-well plates in antibiotic-free medium and transfected with control oligonucleotide (100 nM) or inhibitor (100 nM) using Lipofectamine 2000 (Invitrogen 4 Corporation, California, USA) according to the manufacturer’s recommendation. Luciferase and renilla signals were measured 48 h after transfection using the Annexin V-FITC apoptosis detection kit (Invitrogen Corporation, California, USA) as described by the manufacturer’s instructions. Three independent experiments were performed and the data are presented as the mean + SD.
Western blot analysis
Total cell lysates (50 ug) were fractionated by SDS/PAGE. The proteins were electroblotted onto nitrocellulose membranes and Western blot analyses were carried out according to standard procedures as previously described. β-actin was used as the loading control in the Western blots.
The statistical analyses were performed using the Statistical Package for the Social Sciences software using the two-tailed Student’s t-test. The significance was determined at the 95% confidence interval. All the data were expressed as the mean ± standard deviation (SD) from a representative experiment.
Expression and clinical significance of miR-92b in gliomas
A miR-92b Inhibitor Impeded Cell Viability and Colony Formation and Promoted Apoptosis
MiR -92b directly targeted the DKK3 3′UTR
To test our hypothesis, we analyzed the protein levels of DKK3 and miR-92b in the glioma cells. The results showed a negative correlation between the levels of miR-92b and DKK3 in the glioma cells (Figure 3B). We then decided to test whether DKK3 is a direct target of miR-92b. We first constructed a luciferase reporter in which the nucleotides of the DKK3-3′UTR complementary to miR-92b were inserted into the 3′UTR of PGL3-promoter vector (DKK3-WT). Correspondingly, we also generated both a mutant reporter (DKK3-Mut), in which the sequence in the miR-92b seed region complementary sites was changed (the sequence of the mutated construct is 5′…AGGCUGUGGGUAGAUGCTGAAUA…), and a control reporter (DKK3-Ctrl), which contained a non-related fragment of cDNA. MiR-92b over-expression plasmid was co-transfected with DKK3-WT or DKK3-Mut or DKK3-Ctrl into cells. The assays showed that the luciferase activity in the DKK3-WT transfected cells significantly decreased compared to the luciferase activity in the mutant and negative control cells and vice verse, suggesting that miR-92b reduced the luciferase activity of DKK3-WT but had no effect on DKK3-Mut (Figure 3C). Therefore, we concluded that the DKK3 is the target of miR-92b.
MiR-92b inhibitor impeded the Wnt/beta-catenin signaling pathway by targeting DKK3
MicroRNAs play a crucial role in the process of tumor formation. They impact the dynamic balance between oncogenes and tumor suppressor genes by degrading target genes, thereby contributing to cancer progression. Previous studies have shown that miR-92b is over-expressed in brain primary tumor, as compared to primary tumors from other tissues and their metastases to the brain. Based on topological and functional analyses, it was also reported that miR-92b could play important roles related to the Notch signaling pathway in Glioblastoma multiforme (GBM) tumors. However, there were no reports about the association of miR-92b and survival.
In our study, we focused on the regulatory mechanisms of the miR-92b in gliomas. Initially, the miRNA array results showed that miR-92b was upregulated in gliomas, which suggested that miR-92b could play an important role in the development of gliomas as an oncogene. Thus, we hypothesized that the downregulation of miR-92b could promote apoptosis, providing a potential strategy for glioma treatment. In vitro, our studies demonstrated that the miR-92b inhibitor significantly promoted apoptosis and impeded cell viability and colony formation. To determine how miR-92b was involved in the development of gliomas, we used TargetScan and predicted that DKK3 was a probable target of miR-92b in the 3!UTR of DKK3. We proved that the miR-92b overexpression resulted in the downregulation of DKK3 at the protein level, whereas the functional inhibition of miR-92b led to the inhibition of DKK3, strongly suggesting that DKK3 is regulated by miR-92b in gliomas. Meanwhile, a dual luciferase reporter assay identified DKK3 as a direct target of miR-92b.
DKK3 is a critical antagonist of the Wnt/beta-catenin signaling pathway, which has been shown to be inhibited by miR-92b in neuroblastomas, but the mechanism in gliomas has not been elucidated fully. A previous study showed that the Wnt/beta-catenin signaling pathway was activated in gliomas. Thus, we speculated that miR-92b played its role by regulating the Wnt/beta-catenin signaling pathway. To elucidate the mechanism, we detected the protein level of beta-catenin and the downstream genes of the Wnt/beta-catenin signaling pathway, such as Bcl2, c-myc, c-Jun and p-c-Jun. The results showed that the overexpression of miR-92b inhibited DKK3 and increased the expression of beta-catenin (Figure 4A), which suggested that miR-92b modulated beta-catenin via DKK3. To verify whether miR-92b could modulate the Wnt/beta-catenin signaling pathway, we measured the expression of the downstream genes Bcl2, c-myc, c-Jun and p-c-Jun by Western blotting. The results showed that the miR-92b inhibitor could modulate the expression of these genes. The protein expression of Bcl-2, which is not only a downstream gene of the Wnt/beta-catenin signaling pathway but is also an anti-apoptotic gene, was inhibited by miR-92b. This demonstrated that miR-92b could modulate the genes downstream of the Wnt/beta-catenin signaling pathway. Furthermore, it could modulate apoptosis. To testify how miR-92b affected apoptosis, we analyzed the apoptotic genes Caspase-3 and Bax. The results demonstrated that miR-92b increased the expression of Caspase-3 and Bax, indicating that Caspase-3 was activated after treatment with the miR-92b inhibitor (Figure 4B).
Recent data showed miR-92b could regulate Wnt/beta-catenin signaling via Nemo-like kinase. However, the significance of miR-92b in prognostic determination have not been shown in glioma. In this study, our data suggest that a high miR-92b expression level might be a valuable marker for pathological diagnosis and prognosis prediction in high-grade glioma; high miR-92b expression levels were significantly associated with poor survival in high-grade glioma patients as determined by Kaplan-Meier analysis.
In summary, our data demonstrated that the miR-92b could regulated glioma cell proliferation, apoptosis by directly targeting DKK3. We also provide direct evidence that high levels of miR-92b expression are significantly associated with poorer overall survival. To conclude, our data suggest that miR-92b could be a intrinsic regulator of progression in glioma cells and could function as a potential target and predictor of survival in glioma.
This work was supported by the National Key Basic Research Program (NKBRP; 2010CB945203), the National Natural Science Foundation of China (81271382), the Program of Shanghai Subject Chief Scientist (09XD1403300) and the Dr. Innovation fund of Shanghai jiaotong university school of medicine (BXJ201223).
- Geiger GA: Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system. Cancer Res. 2008, 9: 3396-3404.View ArticleGoogle Scholar
- Zheng Y: TGF-alpha induces upregulation and nuclear translocation of Hes1 in glioma cell. Cell Biochem Funct. 2008, 6: 692-700.View ArticleGoogle Scholar
- Eyler CE: Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells. 2008, 12: 3027-3036.View ArticleGoogle Scholar
- Zhao C: Computational prediction of MicroRNAs targeting GABA receptors and experimental verification of miR-181, miR-216 and miR-203 targets in GABA-A receptor. BMC Res Notes. 2012, 5: 91-10.1186/1756-0500-5-91.PubMed CentralView ArticlePubMedGoogle Scholar
- Krutzfeldt J: Strategies to determine the biological function of microRNAs. Nat Genet. 2006, 38 (Suppl): S14-S19.View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 2: 281-297.View ArticleGoogle Scholar
- Baley J: MicroRNAs and ovarian function. J Ovarian Res. 2012, 5: 8-10.1186/1757-2215-5-8.PubMed CentralView ArticlePubMedGoogle Scholar
- Liu S: Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia. 2012, 1: 15-21.View ArticleGoogle Scholar
- Karius T: MicroRNAs in cancer management and their modulation by dietary agents. Biochem Pharmacol. 2012, 12: 1590-1601.Google Scholar
- Ha TY: MicroRNAs in human diseases: from lung, liver and kidney diseases to infectious disease, sickle cell disease and endometrium disease. Immune Netw. 2011, 6: 309-323.View ArticleGoogle Scholar
- Zhang Q: Expression and significance of microRNAs in the p53 pathway in ovarian cancer cells and serous ovarian cancer tissues. Zhonghua Zhong Liu Za Zhi. 2011, 12: 885-890.Google Scholar
- Cho WC: Exploiting the therapeutic potential of microRNAs in human cancer. Expert Opin Ther Targets. 2012, 4: 345-350.View ArticleGoogle Scholar
- Benetatos LE: DLK1-MEG3 imprinted domain microRNAs in cancer biology. Crit Rev Eukaryot Gene Exp. 2012, 1: 1-15.View ArticleGoogle Scholar
- Berezikov E: Phylogenetic shadowing and computational identification of human microRNA genes. Cell. 2005, 1: 21-24.View ArticleGoogle Scholar
- Lim LP: Vertebrate microRNA genes. Science. 2003, 5612: 1540-View ArticleGoogle Scholar
- Lewis BP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005, 1: 15-20.View ArticleGoogle Scholar
- Xie X: Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature. 2005, 7031: 338-345.View ArticleGoogle Scholar
- Spahn M: Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer. 2010, 2: 394-403.Google Scholar
- Takamizawa : Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004, 11: 3753-3756.View ArticleGoogle Scholar
- Inamura K: let-7 microRNA expression is reduced in bronchioloalveolar carcinoma, a non-invasive carcinoma, and is not correlated with prognosis. Lung Cancer. 2007, 3: 392-396.View ArticleGoogle Scholar
- Nass D: MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors. Brain Pathol. 2009, 3: 375-383.View ArticleGoogle Scholar
- Haug BH: MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis. 2011, 7: 1005-1012.View ArticleGoogle Scholar
- Kroemer G: Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007, 1: 99-163.View ArticleGoogle Scholar
- Liang X: B1, a novel amonafide analogue, overcomes the resistance conferred by Bcl-2 in human promyelocytic leukemia HL60 cells. Mol Cancer Res. 2010, 12: 1619-1632.View ArticleGoogle Scholar
- Nakamura RE: Analysis of Dickkopf3 interactions with Wnt signaling receptors. Growth Factors. 2010, 4: 232-242.View ArticleGoogle Scholar
- Ueno K: Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog. 2011, 6: 449-457.View ArticleGoogle Scholar
- Lambiv WL: The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. Neuro Oncol. 2011, 7: 736-747.View ArticleGoogle Scholar
- Gotze S: Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer. 2010, 11: 2584-2593.Google Scholar
- Utsuki S: Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol. 2002, 3: 187-192.View ArticleGoogle Scholar
- Gregory RI: MicroRNA biogenesis and cancer. Cancer Res. 2005, 9: 3509-3512.View ArticleGoogle Scholar
- Sun J: Uncovering MicroRNA and transcription factor mediated regulatory networks in glioblastoma. PLoS Comput Biol. 2012, 7: e1002488-View ArticleGoogle Scholar
- Lee EJ: Dkk3, downregulated in cervical cancer, functions as a negative regulator of beta-catenin. Int J Cancer. 2009, 2: 287-297.View ArticleGoogle Scholar
- Sareddy GR: Activation of Wnt/beta-catenin/Tcf signaling pathway in human astrocytomas. Neurochem Int. 2009, 5: 307-317.View ArticleGoogle Scholar
- Wang K: miR-92b controls glioma proliferation and invasion through regulating Wnt/beta-catenin signaling via Nemo-like kinase. Neuro Oncol. 2013, EpubGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.